Floatz logo

Gilteritinib

Acute Myeloid Leukemia With FLT3/ITD Mutation

The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Acute Myeloid Leukemia With FLT3/ITD Mutation cohort.

Asset / SponsorPhaseRating
Azacitidine
French Innovative Leukemia Organisation
Phase 2BB
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 3BB
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3BB
xy0206
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase 3BB
Daunorubicin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB

View all 23 →

Same molecule, other indications

Gilteritinib is also rated in:

myelodysplastic syndrome with excess blasts-2Dormant
BB
Indicative ·
66 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
65 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →